

Table 36. Culture-Positive Tuberculosis Cases and Percentages with Drug-Susceptibility Results, by Resistance to INH or Multidrug Resistance: Reporting Areas, 2010

Reporting Area	Total Culture Positive Cases	Cases with Initial Drug-Susceptibility Testing Performed ¹		Resistance ²			
				Isoniazid ¹		Isoniazid and Rifampin ¹	
		No.	(%)	No.	(%)	No.	(%)
United States	8,413	8,063	(95.8)	667	(8.3)	107	(1.3)
Alabama	117	116	(99.1)	5	(4.3)	0	(0.0)
Alaska	52	51	(98.1)	3	(5.9)	1	(2.0)
Arizona	201	194	(96.5)	15	(7.7)	0	(0.0)
Arkansas	56	56	(100.0)	1	(1.8)	0	(0.0)
California	1,843	1,799	(97.6)	174	(9.7)	25	(1.4)
Colorado	51	51	(100.0)	6	(11.8)	1	(2.0)
Connecticut	77	74	(96.1)	9	(12.2)	5	(6.8)
Delaware	13	13	(100.0)	0	(0.0)	0	(0.0)
District of Columbia	32	29	(90.6)	2	(6.9)	1	(3.4)
Florida	634	602	(95.0)	37	(6.1)	5	(0.8)
Georgia	293	288	(98.3)	23	(8.0)	3	(1.0)
Hawaii	79	74	(93.7)	0	(0.0)	0	(0.0)
Idaho	11	11	(100.0)	0	(0.0)	0	(0.0)
Illinois	277	265	(95.7)	22	(8.3)	2	(0.8)
Indiana	63	61	(96.8)	3	(4.9)	0	(0.0)
Iowa	27	24	(88.9)	1	(4.2)	0	(0.0)
Kansas	40	40	(100.0)	2	(5.0)	0	(0.0)
Kentucky	75	72	(96.0)	6	(8.3)	2	(2.8)
Louisiana	155	136	(87.7)	13	(9.6)	1	(0.7)
Maine	4	4	(100.0)	0	(0.0)	0	(0.0)
Maryland	162	159	(98.1)	11	(6.9)	0	(0.0)
Massachusetts	171	169	(98.8)	14	(8.3)	0	(0.0)
Michigan	129	125	(96.9)	10	(8.0)	2	(1.6)
Minnesota	109	109	(100.0)	5	(4.6)	0	(0.0)
Mississippi	82	82	(100.0)	5	(6.1)	1	(1.2)
Missouri	75	34	(45.3)	--	--	--	--
Montana	5	5	(100.0)	0	(0.0)	0	(0.0)
Nebraska	14	13	(92.9)	0	(0.0)	0	(0.0)
Nevada	74	72	(97.3)	11	(15.3)	1	(1.4)
New Hampshire	8	8	(100.0)	3	(37.5)	0	(0.0)
New Jersey	315	310	(98.4)	32	(10.3)	8	(2.6)
New Mexico	44	44	(100.0)	3	(6.8)	1	(2.3)
New York State ³	170	169	(99.4)	15	(8.9)	3	(1.8)
New York City	501	488	(97.4)	48	(9.8)	11	(2.3)
North Carolina	215	207	(96.3)	15	(7.2)	1	(0.5)
North Dakota	8	7	(87.5)	0	(0.0)	0	(0.0)
Ohio	143	142	(99.3)	11	(7.7)	3	(2.1)
Oklahoma	58	54	(93.1)	4	(7.4)	1	(1.9)
Oregon	60	60	(100.0)	4	(6.7)	0	(0.0)
Pennsylvania	191	160	(83.8)	14	(8.8)	4	(2.5)
Rhode Island	19	19	(100.0)	0	(0.0)	0	(0.0)
South Carolina	112	101	(90.2)	5	(5.0)	0	(0.0)
South Dakota	11	11	(100.0)	1	(9.1)	0	(0.0)
Tennessee	135	135	(100.0)	13	(9.6)	3	(2.2)
Texas	1,007	957	(95.0)	76	(7.9)	12	(1.3)
Utah	18	18	(100.0)	6	(33.3)	2	(11.1)
Vermont	4	4	(100.0)	0	(0.0)	0	(0.0)
Virginia	215	189	(87.9)	12	(6.3)	0	(0.0)
Washington	197	193	(98.0)	20	(10.4)	5	(2.6)
West Virginia	12	11	(91.7)	0	(0.0)	0	(0.0)
Wisconsin	46	45	(97.8)	5	(11.1)	2	(4.4)
Wyoming	3	3	(100.0)	0	(0.0)	0	(0.0)
American Samoa ⁴	2	2	(100.0)	0	(0.0)	0	(0.0)
Fed. States of Micronesia ⁴	64	58	(90.6)	3	(5.2)	1	(1.7)
Guam ⁴	57	53	(93.0)	5	(9.4)	2	(3.8)
Marshall Islands ⁴	70	68	(97.1)	2	(2.9)	1	(1.5)
N. Mariana Islands ⁴	18	17	(94.4)	0	(0.0)	0	(0.0)
Puerto Rico ⁴	73	72	(98.6)	7	(9.7)	0	(0.0)
Republic of Palau ⁴	13	12	(92.3)	0	(0.0)	0	(0.0)
U.S. Virgin Islands ⁴

¹Patients tested to at least isoniazid and rifampin

²Isolates may be resistant to other drugs. Overall U.S. percentage based on 52 reporting areas (50 states, New York City, and the District of Columbia). Counts and percentages shown only for reporting areas with information reported for ≥75% of cases.

³Excludes New York City.

⁴Not included in U.S. totals.

Note: Ellipses indicate data not available.